Having trouble accessing articles? Reset your cache.

Baxter's Gammagard fails in Phase III AD trial

Baxter International Inc. (NYSE:BAX) said both 200 and 400 mg/kg doses of IV Gammagard Liquid 10% given every two weeks missed the co-primary endpoints in

Read the full 256 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE